<DOC>
	<DOCNO>NCT02254434</DOCNO>
	<brief_summary>This study evaluate pharmacokinetics eltrombopag 50 mg oral administration Mexican healthy volunteer fast condition . The study open label , single dose study 26 subject plan enrol . Healthy subject ( male female ) age 18 - 50 year age ( inclusive ) Body Mass Index within range 18-27.0 kg/meter ( ) ^2 ( inclusive ) enrol accord Quetelet . REVOLADE register trademark GSK group company .</brief_summary>
	<brief_title>A Pharmacokinetic Study Eltrombopag 50 Milligram ( mg ) Healthy Volunteers Under Fasting Conditions</brief_title>
	<detailed_description />
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Subjects ' participation must voluntary accord General Health Law inform consent form must obtain subject participation . Compliance HelsinkiÂ´s Declaration , Japan Review good clinical practice ( GCP ) follow . Mexican male female healthy volunteer 18 50 year old include . A female subject eligible participate , Nonchildbearing potential define pre menopausal female document tubal ligation hysterectomy ( definition , `` document '' refers outcome investigator's/designee 's review subject 's medical history study eligibility , obtain via verbal interview subject subject 's medical record ] ; postmenopausal define 12 month spontaneous amenorrhea ( questionable case blood sample simultaneous follicle stimulate hormone [ FSH ] &gt; 40 milliinternational unit per milliliter ( MlU/ml ) estradiol &lt; 40 picogram per milliliter [ pg/ml ] [ &lt; 147 picomole per liter ( pmol/L ) ] confirmatory ) . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method describe Investigator/designee , wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrollment . For form HRT , least 24 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method ) . Childbearing potential negative pregnancy test determine ( serum urine ) human chorionic gonadotropin ( hCG ) test screen prior dose abbr de ante meridiem ( AN ) . Agrees use one contraception method list Investigator/designee appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception seven day drug administration . samesex partner , prefer usual lifestyle . Body mass index ( BMI ) 1827.0 kilogram per meter ( kg/m^2 ) accord Quetelet . Volunteers healthy determine medical evaluation do physician center safety labs result do certified local laboratory . Variation limit within normal range screen visit : Blood pressure ( BP ) ( seat ) 90 130 millimeter mercury ( mm Hg ) Systolic pressure 60 90 mmHg diastolic pressure , heart rate ( HR ) 55 100 beat per minute ( bpm ) respiratory rate ( RR ) 14 20 per minute . Safety laboratory test do include : Hematology : Complete blood count differential , Hemoglobin , Hematocrit , platelet count , etc ; Blood chemistry : Albumin , Alkaline phosphatase , aspartateaminotransferase ( AST ) , alanine aminotransferase ( ALT ) , Urea , Calcium , Chloride , Glucose , Phosphate , Potassium , Serum creatinine , Sodium , Total bilirubin , Total protein , etc ; Urinalysis : pH , Specific gravity , Protein , Glucose , Ketones , Bilirubin , Occult blood cell , Nitrite , Urobilinogen , Leukocytes , Microscopic examination ; Hepatitis B C test ; human Immunodeficiency Virus ( HIV ) test ; Serum pregnancy test ; Drug abuse test ; Alcohol detection test ; Urine Pregnancy test ; ECG ; Chest X ray . Normal variation limit laboratory value +/ 10 % normal range , unless principal investigator ( PI ) consider another deviation clinically nonsignificant . In case , value document volunteer 's clinical file well decision include subject prior consult GlaxoSmithKline ( GSK ) Medical Monitor . For safety reason per PI criterion additional ECG safety lab may perform . Subjects change vital sign compare obtain screen visit . Volunteers comply inclusion criterion describe previously Volunteers history clinically relevant cardiovascular , renal , hepatic , muscular , metabolic . Clinically relevant hematologic , gastrointestinal , neurological , endocrine , pulmonary , mental disease organical abnormality . Volunteers muscular traumatism within 21 day study . Volunteers require drug study , besides study drug . Volunteers dyspepsia , gastritis , esofagitis , duodenal gastric ulcer . Volunteers receive hepatic metabolism drug inhibitor inducer within 30 day begin study receive drug may alter urinary pH , like antiacid sodium bicarbonate , potasium citrate certain diuretic Volunteers receive drug 7 half life complete begin study . Volunteers ALT , alkaline phosphatase bilirubin &lt; = 1.5x upper limit normal range ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Corrected QT interval duration ( QTc ) value triplicate ECGs obtain brief recording period : QTc &lt; 450 millisecond ( msec ) ; QTc &lt; 480 msec subject Bundle Branch Block . Volunteers might require hospitalized reason within 6 month begin study Subjects previous participation another research study within 60 day prior begin study . Subjects allergic food , drug and/or substance Subjects know history sensitivity heparin heparininduced thrombocytopenia . Subjects consume alcohol , coffee , grapefruit , nicotine , orange metilxantines contain substance ( coffee , tea , chocolate , cola product , broil product etc ) within 72 hour prior confinement period end study . Subjects might lose donated 450 ml blood within 60 day prior begin study . Alcohol drug abuse history Volunteers require special meal ( vegetarian ) . Unwillingness unable understand nature , objectives possible consequence study . Evidence able cooperate study Positive alcohol , drug abuse and/or pregnancy test Breast feed Volunteers kind hormonal therapy Volunteers register COFEPRIS web page</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>single-dose</keyword>
	<keyword>fast</keyword>
	<keyword>eltrombopag 50 mg</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>healthy volunteer</keyword>
	<keyword>Open-label</keyword>
</DOC>